Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)
Shots:
- The KEYNOTE-224 study involves assessing of Keytruda (200mg q3w @24mos) in 104 patients with HCC aged ≥65- previously treated or intolerant to sorafenib
- KEYNOTE-224 study results: ECOG PS 0 or 1 (61% or 39%); Child Pugh class A5/A6/B7/B8 (72%/22%/5%/1%); HBV & HCV seropositive (21% & 25%); ORR (17%); CR (1%); PR (16%); mDOR @ 6mos.&12mos. (89% & 56%)
- Keytruda is a mAb- works as an anti-PD -1 therapy for tumor cells and has received 14 approvals including one for HCC & is evaluated in > 850 trials in for different cancers
Ref: Merck | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com